Diplomat Pharmacy Inc (DPLO) 29.53 $DPLO Diplomat

New Post Public Reply Private Reply Replies (0) Message Board

Sep 22, 2016 at 7:07 PM

Diplomat Pharmacy Inc (DPLO) 29.53 $DPLO

Diplomat Extends Oncology Campaign to Honor Patients
PR Newswire - Tue Sep 06, 3:30PM CDT
Diplomat Pharmacy, Inc. (NYSE: DPLO) is extending its campaign to increase awareness of Diplomat in the oncology market and to honor patients who suffer from cancer, with a focus this month on multiple myeloma.
DPLO: 29.53 (+0.48)

Diplomat to Participate in Upcoming Investor Conferences
PR Newswire - Wed Aug 24, 1:00PM CDT
Diplomat Pharmacy, Inc. (NYSE: DPLO), the nation's largest independent specialty pharmacy, has announced that Phil Hagerman, chairman and CEO, and Sean Whelan, CFO, will present at four upcoming investor conferences.
DPLO: 29.53 (+0.48)

Diplomat to Dispense ZINBRYTA(TM) for the Treatment of Multiple Sclerosis
PR Newswire - Mon Aug 15, 7:00AM CDT
Diplomat Pharmacy, Inc. (NYSE: DPLO) is now filling prescriptions for ZINBRYTA(TM) (daclizumab), which was recently approved by the Food and Drug Administration. ZINBRYTA is an interleukin-2 receptor-blocking antibody indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (MS).
DPLO: 29.53 (+0.48)

Diplomat Announces 2nd Quarter Financial Results
PR Newswire - Tue Aug 09, 3:15PM CDT
Diplomat Pharmacy, Inc. (NYSE: DPLO), the nation's largest independent specialty pharmacy, announced financial results for the quarter ended June 30, 2016. All comparisons, unless otherwise noted, are to the quarter ended June 30, 2015.
DPLO: 29.53 (+0.48)

Diplomat to Recognize Patients with World Hepatitis Day Campaign
PR Newswire - Thu Jul 28, 7:00AM CDT
Diplomat Pharmacy, Inc. (NYSE: DPLO) is recognizing World Hepatitis Day with a campaign to raise awareness of the disease and honor patients who have felt its effects. World Hepatitis Day occurs annually July 28.
DPLO: 29.53 (+0.48)

Diplomat Launches Month-Long Campaign to Honor Cancer Patients
PR Newswire - Mon Jun 06, 3:30PM CDT
Diplomat Pharmacy, Inc. (NYSE: DPLO) announced today that it is launching a month-long campaign to celebrate National Cancer Survivors Day and the people touched by the disease. The company also released a video highlighting one of their own patients' personal stories and her experience with acute myeloid leukemia.
DPLO: 29.53 (+0.48)

Why Investors Have This Drug Makers' Stocks on Their Radar? - Carbylan Therapeutics, Catalent Inc., Medicines Co., and Diplomat Pharmacy
PR Newswire - Mon Jun 06, 7:00AM CDT
The Generic Drugs space is an attractive yet very competitive industry. In today's lineup, ActiveWallSt.com have these companies: Carbylan Therapeutics Inc. (NASDAQ: CBYL), Catalent Inc. (NYSE: CTLT), The Medicines Co. (NASDAQ: MDCO), and Diplomat Pharmacy Inc. (NYSE: DPLO). Learn more about these stocks and receive your complimentary trade alerts at:
MDCO: 41.50 (+0.54), DPLO: 29.53 (+0.48), CTLT: 26.63 (+0.09), CBYL: 0.48 (+0.01)

Diplomat Completes Acquisition of TNH Advanced Specialty Pharmacy
PR Newswire - Wed Jun 01, 3:30PM CDT
Diplomat Pharmacy, Inc. (NYSE: DPLO), announced today it has completed the acquisition of Valley Campus Pharmacy, Inc., doing business as TNH Advanced Specialty Pharmacy ("TNH"

, a leading specialty pharmacy that provides individualized patient care, based in Van Nuys, California.
DPLO: 29.53 (+0.48)

Diplomat to Host First "Diplomat Dialogue" in Honor of National Cancer Survivors Day
PR Newswire - Tue May 31, 3:36PM CDT
Diplomat Pharmacy, Inc. (NYSE: DPLO) announced today its first "Diplomat Dialogue," a video conversation slated for June 7, 2016, to take a closer look at one patient's journey. The event, hosted live from noon to 1 p.m. ET, will focus on a man named Jay and the care team who helped him along the road to wellness.
DPLO: 29.53 (+0.48)

Diplomat to Participate in the William Blair 36th Annual Growth Stock Conference
PR Newswire - Tue May 31, 1:00PM CDT
Diplomat Pharmacy, Inc. (NYSE: DPLO), the nation's largest independent specialty pharmacy, has announced that Phil Hagerman, Chairman & CEO, and Sean Whelan, CFO, will present at the upcoming William Blair 36th Annual Growth Stock Conference in Chicago, IL.
DPLO: 29.53 (+0.48)

Diplomat Launches 3rd Annual Fellowship and Internship Programs
PR Newswire - Mon May 23, 3:30PM CDT
Diplomat Pharmacy, Inc. (NYSE: DPLO) announced today the start of the third annual Fellowship and Internship programs. The hands-on learning experience is a 12-week summer program, May 23-Aug. 12.
DPLO: 29.53 (+0.48)

Diplomat's Hepatitis C Coverage Study with Penn Medicine Published and Chosen as Top Editor's Pick
PR Newswire - Wed May 18, 3:30PM CDT
Diplomat Pharmacy, Inc. (NYSE: DPLO) announced the publication of its collaborative study with the Perelman School of Medicine at the University of Pennsylvania on insurance coverage for hepatitis C.
DPLO: 29.53 (+0.48)

Smith Drug Company Partners With Diplomat Pharmacy Inc. to Bring Specialty Pharmacy to Independent Retail Pharmacies
Marketwired - Mon May 16, 8:20AM CDT
Customers Can Now Offer Comprehensive Patient Care and Clinical Expertise for Specialty Prescriptions
DPLO: 29.53 (+0.48)

Diplomat Pharmaceuticals posts 1Q profit
Automated Insights - Mon May 09, 3:53PM CDT
FLINT, Mich. (AP) _ Diplomat Pharmacy Inc. (DPLO) on Monday reported first-quarter net income of $15.4 million.
DPLO: 29.53 (+0.48)

Diplomat Announces 1st Quarter Financial Results
PR Newswire - Mon May 09, 3:15PM CDT
Diplomat Pharmacy, Inc. (NYSE: DPLO), the nation's largest independent specialty pharmacy, announced financial results for the quarter ended March 31, 2016. All comparisons, unless otherwise noted, are to the quarter ended March 31, 2015.
DPLO: 29.53 (+0.48)

Diplomat Celebrates World Hepatitis Month with National Multimedia Campaign
PR Newswire - Tue May 03, 8:00AM CDT
Diplomat Pharmacy, Inc. (NYSE: DPLO) announced today that it is celebrating Hepatitis Awareness Month with a campaign to honor patients and caregivers. The company released a video of two patients who tell their personal story and encourage those at risk to get tested and begin the road to a life free of hepatitis.
DPLO: 29.53 (+0.48)

Diplomat to Acquire Oncology-Focused TNH Advanced Specialty Pharmacy
PR Newswire - Thu Apr 28, 3:30PM CDT
Click here for supplemental information regarding the transaction. Diplomat Pharmacy, Inc. (NYSE: DPLO), the nation's largest independent specialty pharmacy, announced today that it has signed a definitive agreement to acquire Valley Campus Pharmacy, Inc., doing business as TNH Advanced Specialty Pharmacy ("TNH"

, a leading specialty pharmacy that provides individualized patient care, based in Van Nuys, California. In 2015, TNH generated approximately $400 million in revenue. The transaction is expected to close in the next 30 to 60 days and is expected to be accretive to Diplomat's earnings per share in 2016.
DPLO: 29.53 (+0.48)

Diplomat Announces Executive Promotion for Jennifer Hagerman
PR Newswire - Tue Apr 26, 3:30PM CDT
Diplomat Pharmacy, Inc. (NYSE: DPLO) is pleased to announce the promotion of Jennifer Hagerman, Pharm D., to Vice President of Education and Quality.
DPLO: 29.53 (+0.48)

Diplomat to Dispense VENCLEXTA(TM) for the Treatment of Chronic Lymphocytic Leukemia
PR Newswire - Tue Apr 19, 7:00AM CDT
Diplomat Pharmacy, Inc. (NYSE: DPLO) announced today that it is now filling prescriptions for VENCLEXTA(TM) (venetoclax). VENCLEXTA(TM) was recently approved by the U.S. Food and Drug Administration for the treatment of people with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy, including those with 17p deletion.
DPLO: 29.53 (+0.48)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

ASTS Faces Class Action; Investors Beware of Pitfalls

Securities Fraud Allegations Hit AST SpaceMobile Days like this remind me why we keep our eyes peeled in the stock game—AST SpaceMobile (NASDAQ: ASTS) is tangled in a web of legal drama, and it's something you can't brush off with a shrug. Class action lawsuits for securities fraud? That's like finding out the foundation's shaky beneath a skyscraper. If you've got skin...

Innovent's SINTBILO® Hits Primary Endpoint in Study

Innovent's Latest Breakthrough with SINTBILO® One moment you're sipping coffee, the next you're staring at a clinical milestone. Innovent Biologics has shouted from the rooftops that their drug, SINTBILO® (tafolecimab injection), has wrapped up its Phase 3 CREDIT-5 study, snagging the primary endpoint with both hands. This isn't just any drug; it's marked as the first...

Intelligent Communication Forum Eyes Global Ecosystem Shift

China's Grand Vision for Intelligent Communication You know what they say about big ideas—they start in the most bustling of places. And here we are in Wuxi, a city's pulse pounding with ambition, hosting the 2026 China International Intelligent Communication Forum. Picture it: From November 8th to 10th, movers, shakers, and visionaries are scribbling new blueprints for...

Xiaomi's Smart Auto Factory Draws Global Media Praise

Xiaomi Impresses Global Media in Beijing Factory Tour In the ever-changing world of NEVs (New Energy Vehicles), a tour of Xiaomi's smart auto factory in Beijing has made waves among global media folks. These scribes got an up-close look at Xiaomi's magic mix of tech and style on November 6, part of a grand media gathering. What's Under the Hood? Marcos Costa de Oliveira,...

Novo's Semaglutide Shows Promise in MASH Study

Semaglutide, a name on the lips of many investors looking for breakthroughs, is making waves again. This time, the stir comes from recent findings in the MASH field, and it's got folks in white coats quite excited. Revolutionary Results from Novo Novo Nordisk has announced promising results from their phase 3 ESSENCE trial that looks into semaglutide's effects on a...

GlycoNex Eyes Japanese Market with Denosumab Biosimilar

A Strategic Step into the Japanese Market Alright folks, there's a new kid aiming to shake things up in the biotech neighborhood, and it's GlycoNex with its denosumab biosimilar, SPD8. These guys just tossed their hat in the ring with a regulatory submission to Japan's Pharmaceuticals and Medical Devices Agency (PMDA). If the cosmic forces align, they might snag an...

Allergan Aesthetics Study Shows Rising Patient Satisfaction

Enhanced Patient Satisfaction with Aesthetic Treatments Dive into the latest studies from Allergan Aesthetics—AbbVie's heavyweight in the beauty battleground. If you've got an ounce of optimism left in this market, their recent findings might just lift your spirits. Phase 4 studies, namely HARMONY IN DIVERSITY and HALO, are showing highly positive results among patients...

Webull Faces Class Action Suit: Key Deadlines Loom

The Clock is Ticking for Webull Investors If anyone's got a Webull stake, listen up! You’ve got a deadline that's staring you in the face: December 7, 2026. This is when you need to throw your hat in the ring to be a lead plaintiff in the Webull Corporation class action. We're talking securities fraud, folks, with allegations flying that would make your head spin....

D-Wave's Legal Trouble: Securities Fraud Suit Looms

A Looming Legal Storm for D-Wave Investors Call it another day, another legal tangle in the investing world. This time, it's D-Wave Quantum Inc. (NASDAQ: QBTS) on the receiving end of a securities fraud class action lawsuit. Yeah, those fancy quantum computers they're pushing didn't predict this one coming. The legal arena is getting ready for a bout, and if you've got...

MWC26 Doha: Bridging Standards for MENA's Future

MWC26 Doha Launches with a Connectivity Mission Forget corporate boardrooms; the real action this week is unfolding in Doha's bustling exhibition halls. Kicked off with the fanfare you'd expect from such a key event, MWC26 Doha has drawn a crowd that's got both tech geeks and policy wonks nodding with interest. This ain’t your average trade show: it’s the melting pot...